Press Release_NEWS



IASO Biotherapeutics Raises $60 Million in Series B Financing led by GL Ventures to Advance Cell Therapies for Cancer Care

Date : 2020-03-23 Views : 237

$NMPA Approves IND Application for CT103A, A Fully-human BCMA CAR-T for the Treatment of Relapsed/Refractory Multiple Myeloma codeveloped by IASO BIO and Innovent Bio$

NMPA Approves IND Application for CT103A, A Fully-human BCMA CAR-T for the Treatment of Relapsed/Refractory Multiple Myeloma codeveloped by IASO BIO and Innovent Bio

Date : 2019-09-11 Views : 232

$Clinical Results of Fully-human BCMA CAR-T for the Treatment of Relapsed/Refractory Multiple Myeloma Co-developed by IASO BIO and Innovent Presented at the 2019 ASCO and EHA Annual Meetings$

Clinical Results of Fully-human BCMA CAR-T for the Treatment of Relapsed/Refractory Multiple Myeloma Co-developed by IASO BIO and Innovent Presented at the 2019 ASCO and EHA Annual Meetings

Date : 2019-06-18 Views : 221